7th International Immunoglobulin Conference: Poster Presentations. (December 2014)

• Record Type: Journal Article
• Authors: Warnatz, K.; Ballow, M.; Stangel, M.; Bril, V.
• Is Part Of: Clinical and experimental immunology. Volume 178(2014)supplement 1
• Page Start: 162
• Page End: 162
• Publication Date: 2014-12
• Subjects: Immunopathology -- Periodicals; 616.079
• DOI: 10.1111/cei.12554
• Languages: English
• ISSNs: 0009-9104

Abstract

Summary: The pan‐European survey provides useful information on the accessibility and trends of intravenous and subcutaneous immunoglobulin (IVIg/SCIg) therapy, which is used to treat primary immunodeficiency disorders (PIDs). Although immunoglobulin (Ig) therapy is the first‐line treatment for PIDs, the mechanisms of action of Ig therapy may differ according to the condition it is used to treat. Moreover, intriguing presentations suggest that further investigation is required to understand more clearly both the haematological and immunoregulatory effects of therapeutic immunoglobulin. This can ultimately provide more information on optimizing Ig therapy efficacy, and establish whether individualized dosing regimens for patients will be conducive to better clinical outcomes. In addition to treating autoimmune and inflammatory conditions, there is evidence to suggest that immunoglobulins can potentially play a role in transplantation, which warrants further investigation for future use.